Journal article
Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus
Abstract
Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by beta-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated …
Authors
See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM
Journal
Journal of General Virology, Vol. 87, No. 3, pp. 641–650
Publisher
Microbiology Society
Publication Date
March 1, 2006
DOI
10.1099/vir.0.81579-0
ISSN
0022-1317
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Administration, IntranasalAnimalsAntibodies, ViralAntibody SpecificityDisease Models, AnimalDrug Evaluation, PreclinicalFemaleImmunoglobulin AInjections, IntramuscularInjections, SubcutaneousMembrane GlycoproteinsMiceNeutralization TestsNucleocapsid ProteinsSevere acute respiratory syndrome-related coronavirusSevere Acute Respiratory SyndromeSpike Glycoprotein, CoronavirusVaccinationVaccines, DNAViral Envelope ProteinsViral Vaccines